DWA
VRDN icon

Dorsey Wright & Associates’s Viridian Therapeutics VRDN Stock Holding History

Dorsey Wright & Associates’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,511
Closed -$46K – 327
2022
Q1 		$46K Buy
+2,511
New +$48.2K 0.01% 220

Other funds holding VRDN

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dorsey Wright & Associates's VRDN Position: Q2 2022 in Review

Dorsey Wright & Associates sold out of Viridian Therapeutics (VRDN) in Q2 2022, closing a stake of 2,511 shares — an estimated $46K sold.

Dorsey Wright & Associates first reported a position in VRDN in Q1 2022 and held it in 1 quarter. The position peaked at $46K in Q1 2022. 84 funds tracked by Wall St. Rank hold VRDN as of Q2 2022.

  • Dorsey Wright & Associates reported no remaining Viridian Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Dorsey Wright & Associates sold 2,511 Viridian Therapeutics shares in Q2 2022, an estimated $46K.
  • Dorsey Wright & Associates first reported a position in Viridian Therapeutics in Q1 2022 and held it in 1 quarter.
  • Dorsey Wright & Associates's Viridian Therapeutics position peaked at $46K in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2022.

Based on Dorsey Wright & Associates's 13F filing for Q2 2022, filed 20 Jul 2022.